Very interesting RAD have gone to TH for the release of this interim data. As @Steini and other posters have rightfully said even with very good data releases in other Bio’s a TH is not often used. Great news such as Complete response or complete remission is usually not even enough to halt trading.
Afew Possibilities and things to consider.
- The fact the data has to been given to the scientists running the conference prior to its release at the conference could force a halt as they are privy to this material information earlier than the market. Good thing is we find out tomorrow more about the headline data. Although, we will have to wait until the conference for a deep dive 26/28 Oct.
- The release in September advising of the data to be presented at the conference States it is in an imaging trial. Yet in Ricardo’s statement he mentions theranostic. So we could see some earlier than expected therapeutic outcomes such as very good efficacy data. Complete response or complete remission.
- Also In the September release it mentions “as well as being published in a peer review journal” Due to this new molecule’s novel innovative approach it could be significant enough to make the front page of something like Science translational medicine journal. And the TH is in place prior to publishing release.
- Left field negative new development like adverse safety. Highly doubt this as it been chosen for a peer review journal and a conference.
- New information on therapeutic variations or new trails based on the successful findings of this study.
“We are very pleased to see a new molecule and an innovative mode of action in an area of high unmet medical need and we cannot wait to see the data presented” said Radiopharm’s CEO & Managing Director Riccardo Canevari.
“The team at Imperial College London, led by Professor Aboagye, did a tremendous job. F18-Pivalate and its potential therapeutic variations, currently under development, represent a promising theranostic approach to target brain metastases and potentially other brain tumors.”
Professor Aboagye added: “We’re very excited to present our interim data soon. A potentially innovative and effective new imaging approach will be more than welcomed in this field.”
Without doing alot of research into past info on this Molecule yet, my guess is any of these posibile outcomes could be driven by positive data around the molecule/modality's ability to overcome the blood brain barrier in a novel way. Which has inhibited some other cancer therapeutic modes like Car-T cell therapy in brain tumours.
In the past few months there has been some great value buying to offset my initial Pre-IPO investment. As trials progress in their extensive pipeline, Market Cap disparity with RAD’s peers like TLX ($1.69b) will be a distant memory.
Good luck all!
